# Piramal Pharma business expansion and growth

> Live situation record from CLSTR: https://clstr.news/situations/piramal-pharma-business-expansion-and-growth
> Updated: 2026-08-18T21:00:16.000Z. Sources: 7. Developments: 2.

Piramal Pharma Limited reported strong financial performance for the first quarter of fiscal year 2027, noting a 17% increase in revenue to ₹2,270 crore and a 72% rise in EBITDA to ₹285 crore. Chairperson Nandini Piramal stated the company had “started FY27 on a strong note,” with growth across its CDMO, complex hospital generics, and consumer-healthcare segments.

Following these financial results, the company expanded its biologics capabilities by acquiring a controlling stake in Yapan Bio Private Limited. By purchasing an additional 40.67% stake for ₹76 crore, Piramal Pharma increased its total equity in the Hyderabad-based CDMO to 74%, transitioning Yapan Bio from an associate to a subsidiary. This acquisition is intended to enhance integrated large molecule services and support the company’s ADCelerate™ platform for antibody-drug conjugate development.

## Timeline

### 2026-08-18: Piramal Pharma acquires controlling stake in Yapan Bio

Piramal Pharma Limited has acquired a controlling 74% stake in Hyderabad-based Yapan Bio for $7.95 million to expand its biologics and vaccine manufacturing capabilities.

7 sources. https://clstr.news/cluster/piramal-pharma-acquires-controlling-stake-in-yapan-bio

### 2026-07-29: Piramal Pharma posts 17% revenue rise and higher EBITDA margin in Q1 FY27

Piramal Pharma posted 17% revenue growth to ₹2,270 crore and a 12.5% EBITDA margin in Q1 FY27, driven by CDMO expansion and strong performance across its generics and consumer‑health businesses.

4 sources. https://clstr.news/cluster/piramal-pharma-posts-17-revenue-rise-and-higher-ebitda-margin-in-q1-fy27

---
Cite as: Piramal Pharma business expansion and growth. CLSTR, https://clstr.news/situations/piramal-pharma-business-expansion-and-growth